Dimensional Fund Advisors LP Has $84,000 Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Dimensional Fund Advisors LP reduced its holdings in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 13.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 76,759 shares of the biotechnology company’s stock after selling 12,302 shares during the period. Dimensional Fund Advisors LP owned about 0.11% of Aclaris Therapeutics worth $84,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in ACRS. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Aclaris Therapeutics during the 1st quarter valued at about $39,000. BNP Paribas Financial Markets boosted its position in shares of Aclaris Therapeutics by 10.9% during the 1st quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company’s stock valued at $299,000 after acquiring an additional 23,747 shares in the last quarter. Deuterium Capital Management LLC acquired a new stake in shares of Aclaris Therapeutics during the 1st quarter valued at about $99,000. Marquette Asset Management LLC acquired a new stake in shares of Aclaris Therapeutics during the 1st quarter valued at about $104,000. Finally, SG Americas Securities LLC boosted its position in shares of Aclaris Therapeutics by 69.5% during the 1st quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 13,461 shares in the last quarter. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Aclaris Therapeutics

In related news, major shareholder Braden Michael Leonard bought 173,730 shares of Aclaris Therapeutics stock in a transaction dated Tuesday, July 30th. The shares were bought at an average cost of $1.30 per share, for a total transaction of $225,849.00. Following the completion of the transaction, the insider now owns 13,776,421 shares of the company’s stock, valued at approximately $17,909,347.30. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last three months, insiders have purchased 321,763 shares of company stock worth $418,823. Corporate insiders own 6.40% of the company’s stock.

Analyst Ratings Changes

ACRS has been the topic of a number of recent analyst reports. StockNews.com upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 25th. HC Wainwright restated a “neutral” rating on shares of Aclaris Therapeutics in a research report on Tuesday, September 17th. Seven investment analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $9.00.

Aclaris Therapeutics Stock Down 1.7 %

NASDAQ:ACRS opened at $1.18 on Wednesday. The firm has a market cap of $84.09 million, a PE ratio of -1.08 and a beta of 0.20. Aclaris Therapeutics, Inc. has a 12 month low of $0.59 and a 12 month high of $5.71. The company’s 50-day moving average price is $1.18 and its two-hundred day moving average price is $1.20.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.04. Aclaris Therapeutics had a negative net margin of 183.28% and a negative return on equity of 53.18%. The company had revenue of $2.77 million for the quarter, compared to analyst estimates of $1.74 million. On average, research analysts expect that Aclaris Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.